Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine
June 19, 2015 at 16:00 PM EDT
[PR Newswire] – THOUSAND OAKS, Calif., June 19, 2015 /PRNewswire/ — Amgen (AMGN) today announced positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Stock Update (NASDAQ:AMGN): Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference